Table I.
Characteristics of the studies included in the systematic review.
| Author, year | Study design | Accrual period | No. of patients | Median follow-up (range), months | ICC features, % | Treatment before SBRT, % | (Refs.) |
|---|---|---|---|---|---|---|---|
| Shen et al, 2017 | Retrospective | 2009-2012 | 28 | 16.0 (3.0-42.0) | Peripheral lesions: 78.6, Central lesions: 21.4 | TACE: 28.6 | (15) |
| Solitary lesions: 71.4 | |||||||
| Multiple lesions: 28.6 | |||||||
| AJCC stage: II 21.4, III | |||||||
| 67.9, IVA 10.7 | |||||||
| Weiner et al, 2016 | Phase I-II | 2012-2014 | 12 | 8.8 (0.3-33.0) | NRS | CHT: 66.7 | (16) |
| Klein et al, 2015 | Prospective | 2003-2011 | 20 | NR | NR | NR | (17) |
| Jung et al, 2014 | Retrospective | 2005-2013 | 33 | 10.0 (1.0-97.0) | NRS | NRS | (18) |
| Sebastian et al, 2019 | Retrospective | 2004-2014 | 27 | 17.0 (NR) | AJCC stage: T1 59.3; T2 25.9; T3 11.1; T4 3.7 | CHT: 40.7 | (19) |
| Kozak et al, 2020 | Retrospective | 2003-2017 | 25 | 18.0 (NR) | Positive nodes: 15.0 | CHT: 24.0 | (20) |
| Surgery: 20.0 | |||||||
| RFA: 7.5 | |||||||
| TACE: 12.5 |
AJCC, American Joint Committee on Cancer (31); CHT, chemotherapy; ICC, intrahepatic cholangiocarcinoma; NR, not reported; NRS, not reported separately; RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy; TACE, trans-arterial chemoembolization.